Oncogenic receptor Tyrosine Kinase (TK) pathways, specifically Epidermal Growth Factor (EGF) pathways, have been explored as targets for therapy of NSCLC, and EGF receptor (EGFR) inhibitors are currently used as first-line therapy options for patients with advanced stages of the disease [10,11]. This evidence concerns the gene TKT and non-small cell lung carcinoma.